Crispr Therapeutics AG (CRSP) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Crispr Therapeutics AG stock $16.98, price $50.07, that is 66.1% below the price, quality 28 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $31.27 – $137.82 · fair‑value band $11.21 – $21.23 · the $50.07 price screens above the $16.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Crispr Therapeutics in your weekly email
Every Wednesday you see whether Crispr Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Show moreShow less
The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.
The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated.
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Stock analysis
Crispr Therapeutics AG (CRSP) currently trades at $50.07, while our model-based Fair Value estimate is $16.98, 66% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $11.21 (bear) to $21.23 (bull), the price of $50.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Crispr Therapeutics AG reported revenue of $3.5M in FY2025 versus $913M in FY2021, a compound −75.1%/yr. Reported net income was −$582M in FY2025.
Key figures
Market cap $4.8B Mid · EPS (TTM) $−4.74 · Return on equity −26.1% · Return on assets (EBIT) −14.5% (5-year average) · Operating margin −1,128% · Revenue growth (YoY) +10.4% · Free cash flow −$346M · Net debt $39.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (medium confidence).
What moves the price
The share trades about 19% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −66%, CRSP screens richer than that median.
Fair Value models
Bear$11.21Fair Value $16.98Bull$21.23
Price $50.07 · Downside -66.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 5 officers or directors sold shares worth $5.1M and none bought.
SaleSamarth KulkarniChief Executive Officer, Director7× since Jan 20, 2026: 179,069 shares, avg. $53.62$9.6MOct 19, 2026
SaleSimeon GeorgeDirector14,514 shares at $49.63$720,373Oct 14, 202610b5-1 plan
SaleJames R. KasingerGeneral Counsel and Secretary7× since Feb 19, 2026: 24,974 shares, avg. $54.92$1.4MOct 14, 2026
SaleAli BehbahaniDirector13,679 shares at $57.09$780,934Sep 17, 2026
SaleNaimish PatelChief Medical Officer2× since Mar 16, 2026: 6,936 shares, avg. $52.28$362,596May 29, 2026
SaleRaju PrasadChief Financial Officer5× since Dec 22, 2025: 88,249 shares, avg. $57.80$5.1MMar 23, 2026
Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−90.0%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.4%
’15
’16
’17
’19
’21
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−49,295.5% (2020) → −16,191.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Gene-editing innovation through CASGEVY revenue growth and CTX310 data forms the core strength while sustained negative free cash flow and minimal revenue scale remain the primary weakness.
Main risk: Persistent adoption questions for the approved CASGEVY therapy risk constraining revenue growth from the Vertex partnership and commercial scale-up.
CRISPR Therapeutics reports rising CASGEVY revenue through its Vertex partnership, yet adoption questions persist for the approved therapy. Its in vivo candidate CTX310 showed durable ANGPTL3 and lipid reductions in phase 1a data, with further results due at the American Heart Association meeting. Does progress on the commercial product outpace the risks in proving the wider pipeline?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside−66.1% · Below median
Profitability
Return on assets−25.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)10.4% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B2.51× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)52· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Crispr Therapeutics AG Fair Value". https://www.fairvalue-calculator.com/stock/CRSP
Frequently asked questions
Is Crispr Therapeutics AG (CRSP) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $16.98 versus a price of $50.07, about 66% lower (overvalued).
What is the fair value of CRSP?
Our model-based fair value for Crispr Therapeutics AG is $16.98 (as of Nov 6, 2026), built from audited fundamentals. The current price: $50.07.
What is the quality score of CRSP?
Crispr Therapeutics AG has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Crispr Therapeutics AG (CRSP)?
Our model-based price target is the fair value of $16.98 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $11.21, optimistic scenario $21.23. It is a calculation from audited fundamentals, not an analyst target.
What is the Crispr Therapeutics AG stock forecast for 2026?
Our models put fair value at $16.98, about 66% lower versus a price of $50.07 (overvalued). Cautious scenario $11.21, optimistic scenario $21.23. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Crispr Therapeutics AG (CRSP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Crispr Therapeutics AG it is $16.98 per share (as of Nov 6, 2026), against a price of $50.07. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Crispr Therapeutics AG stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CRSP trades above its calculated fair value: price $50.07, fair value $16.98, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRSP?
No. The price is what the market pays today ($50.07); the fair value is what the company's own numbers justify ($16.98). For Crispr Therapeutics AG the two are $33.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Crispr Therapeutics AG worth?
The market values Crispr Therapeutics AG at about $4.8B (market capitalisation, as of Nov 6, 2026). Per share that is $50.07; our models calculate a fair value of $16.98 per share.
What do the bullish and bearish scenarios say about CRSP?
Our models span a range for Crispr Therapeutics AG: cautious scenario $11.21, base $16.98, optimistic $21.23 per share (as of Nov 6, 2026, price $50.07). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Crispr Therapeutics AG (CRSP)?
Balance-sheet figures for Crispr Therapeutics AG (as of Nov 6, 2026): return on equity −26.1%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is CRSP from its 52-week high?
Crispr Therapeutics AG trades at $50.07, about 19% below its 52-week high of $61.89 and 13% above the low of $44.34 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $16.98 is for.
Which stocks are comparable to Crispr Therapeutics AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Crispr Therapeutics AG stock attractive at the current price?
The data as of Nov 6, 2026: price $50.07, calculated fair value $16.98 (−66%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRSP calculated?
We run Crispr Therapeutics AG through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $16.98 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Crispr Therapeutics AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Crispr Therapeutics AG (CRSP)?
The closing price on Nov 6, 2026 was $50.07. Our model-based fair value is $16.98, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Crispr Therapeutics AG right now?
The price sits above even our optimistic bull case ($21.23). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($11.21 to $21.23) leaves room in how you read the outcome.
Key figures of Crispr Therapeutics AG
How large is the market capitalisation of Crispr Therapeutics AG (CRSP)?
The market capitalisation of Crispr Therapeutics AG is $4.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Crispr Therapeutics AG (CRSP)?
Earnings per share at Crispr Therapeutics AG are $−4.74. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Crispr Therapeutics AG (CRSP)?
The return on equity (ROE) of Crispr Therapeutics AG is −26.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Crispr Therapeutics AG (CRSP)?
On an EBIT basis the return on assets of Crispr Therapeutics AG is −14.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Crispr Therapeutics AG (CRSP)?
The operating margin of Crispr Therapeutics AG is −1,128% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Crispr Therapeutics AG (CRSP)?
Revenue at Crispr Therapeutics AG is growing +10.4% versus a year earlier (3y avg +100%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Crispr Therapeutics AG (CRSP) generate?
The free cash flow of Crispr Therapeutics AG is −$346M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Crispr Therapeutics AG (CRSP) carry?
The net debt of Crispr Therapeutics AG is $39.7M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Crispr Therapeutics AG in the live analysis
One click puts Crispr Therapeutics AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026
